1
|
Dell’Anno I, Melani A, Martin SA, Barbarino M, Silvestri R, Cipollini M, Giordano A, Mutti L, Nicolini A, Luzzi L, Aiello R, Gemignani F, Landi S. A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma. Cancers (Basel) 2022; 14:2527. [PMID: 35626133 PMCID: PMC9139775 DOI: 10.3390/cancers14102527] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Revised: 05/08/2022] [Accepted: 05/13/2022] [Indexed: 02/04/2023] Open
Abstract
The lack of effective therapies remains one of the main challenges for malignant pleural mesothelioma (MPM). In this perspective, drug repositioning could accelerate the identification of novel treatments. We screened 1170 FDA-approved drugs on a SV40-immortalized mesothelial (MeT-5A) and five MPM (Mero-14, Mero-25, IST-Mes2, NCI-H28 and MSTO-211H) cell lines. Biological assays were carried out for 41 drugs, showing the highest cytotoxicity and for whom there were a complete lack of published literature in MPM. Cytotoxicity and caspase activation were evaluated with commercially available kits and cell proliferation was assayed using MTT assay and by clonogenic activity with standard protocols. Moreover, the five most effective drugs were further evaluated on patient-derived primary MPM cell lines. The most active molecules were cephalomannine, ouabain, alexidine, thonzonium bromide, and emetine. Except for alexidine, these drugs inhibited the clonogenic ability and caspase activation in all cancer lines tested. The proliferation was inhibited also on an extended panel of cell lines, including primary MPM cells. Thus, we suggest that cephalomannine, ouabain, thonzonium bromide, and emetine could represent novel candidates to be repurposed for improving the arsenal of therapeutic weapons in the fight against MPM.
Collapse
Affiliation(s)
- Irene Dell’Anno
- Genetic Unit, Department of Biology, University of Pisa, 56126 Pisa, Italy; (I.D.); (A.M.); (R.S.); (M.C.); (S.L.)
| | - Alessandra Melani
- Genetic Unit, Department of Biology, University of Pisa, 56126 Pisa, Italy; (I.D.); (A.M.); (R.S.); (M.C.); (S.L.)
| | - Sarah A. Martin
- Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK;
| | - Marcella Barbarino
- Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy; (M.B.); (A.G.)
- Translational Oncology, Center for Biotechnology, College of Science and Technology, Temple University, Sbarro Institute for Cancer Research and Molecular Medicine, Philadelphia, PA 19122, USA;
| | - Roberto Silvestri
- Genetic Unit, Department of Biology, University of Pisa, 56126 Pisa, Italy; (I.D.); (A.M.); (R.S.); (M.C.); (S.L.)
| | - Monica Cipollini
- Genetic Unit, Department of Biology, University of Pisa, 56126 Pisa, Italy; (I.D.); (A.M.); (R.S.); (M.C.); (S.L.)
| | - Antonio Giordano
- Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy; (M.B.); (A.G.)
- Translational Oncology, Center for Biotechnology, College of Science and Technology, Temple University, Sbarro Institute for Cancer Research and Molecular Medicine, Philadelphia, PA 19122, USA;
| | - Luciano Mutti
- Translational Oncology, Center for Biotechnology, College of Science and Technology, Temple University, Sbarro Institute for Cancer Research and Molecular Medicine, Philadelphia, PA 19122, USA;
| | - Andrea Nicolini
- Department of Oncology, Transplantations and New Technologies in Medicine, University of Pisa, 56126 Pisa, Italy;
| | - Luca Luzzi
- Department of Medicine, Surgery and Neurosciences, Siena University Hospital, 53100 Siena, Italy;
| | - Raffaele Aiello
- Toma Institute Srl, Via Cesare Rosaroll 24, 80139 Napoli, Italy;
| | - Federica Gemignani
- Genetic Unit, Department of Biology, University of Pisa, 56126 Pisa, Italy; (I.D.); (A.M.); (R.S.); (M.C.); (S.L.)
| | - Stefano Landi
- Genetic Unit, Department of Biology, University of Pisa, 56126 Pisa, Italy; (I.D.); (A.M.); (R.S.); (M.C.); (S.L.)
| |
Collapse
|
3
|
Kim JH, Cho EB, Lee J, Jung O, Ryu BJ, Kim SH, Cho JY, Ryou C, Lee SY. Emetine inhibits migration and invasion of human non-small-cell lung cancer cells via regulation of ERK and p38 signaling pathways. Chem Biol Interact 2015; 242:25-33. [PMID: 26332055 DOI: 10.1016/j.cbi.2015.08.014] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Revised: 07/20/2015] [Accepted: 08/17/2015] [Indexed: 12/12/2022]
Abstract
Emetine is a natural compound originated from ipecac roots. It was commonly used as anti-protozoal and vomiting agent. The apoptosis-inducing effect of emetine makes it considered as a potential anti-cancer agent for various human cancers. Here in this study, we report that emetine inhibits migration and invasion of human non-small-cell lung cancer (NSCLC) cells. Modulation of three major mitogen-activated protein kinases (MAPKs), ERK, p38 and JNK, is well known to be involved in regulation of matrix metalloproteinases (MMPs), which are essential in tissue remodeling and extracellular matrix (ECM) degradation, for cancer cells to spread out from the origin of tumorigenesis. Emetine regulates two major MAPKs, p38 and ERK. Differential inhibition/stimulation of ERK and p38 induced differential suppressions of β-catenin and c-myc transcription factors. This leads to the selective down-regulation of MMP-2 and MMP-9, two major gelatinases which can degrade ECM components, and RECK, a negative regulator of MMP-9.
Collapse
Affiliation(s)
- Ji Hyun Kim
- Department of Life Science, Gachon University, San 65, Bokjeong-Dong, Sujeong-Gu, Seongnam-Si, Gyeonggi-Do, 461-701, South Korea
| | - Eun Byul Cho
- Department of Life Science, Gachon University, San 65, Bokjeong-Dong, Sujeong-Gu, Seongnam-Si, Gyeonggi-Do, 461-701, South Korea
| | - Jongsung Lee
- Department of Genetic Engineering, Sungkyunkwan University, Suwon-Si, Gyeonggi-Do, 440-746, South Korea
| | - Okkeun Jung
- Department of Life Science, Gachon University, San 65, Bokjeong-Dong, Sujeong-Gu, Seongnam-Si, Gyeonggi-Do, 461-701, South Korea
| | - Byung Jun Ryu
- Laboratory of Translational Therapeutics, Korea Research Institute of Chemical Technology, Yuseong-Gu, Daejeon, 305-600, South Korea
| | - Seong Hwan Kim
- Laboratory of Translational Therapeutics, Korea Research Institute of Chemical Technology, Yuseong-Gu, Daejeon, 305-600, South Korea
| | - Jae Youl Cho
- Department of Genetic Engineering, Sungkyunkwan University, Suwon-Si, Gyeonggi-Do, 440-746, South Korea
| | - Chongsuk Ryou
- Department of Pharmacy, College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-Do, 426-791, South Korea
| | - Sang Yeol Lee
- Department of Life Science, Gachon University, San 65, Bokjeong-Dong, Sujeong-Gu, Seongnam-Si, Gyeonggi-Do, 461-701, South Korea.
| |
Collapse
|
4
|
Medel Flores O, Gómez García C, Sánchez Monroy V, Villalba Magadaleno JDA, Nader García E, Pérez Ishiwara DG. Entamoeba histolytica P-glycoprotein (EhPgp) inhibition, induce trophozoite acidification and enhance programmed cell death. Exp Parasitol 2013; 135:532-40. [DOI: 10.1016/j.exppara.2013.08.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Revised: 08/15/2013] [Accepted: 08/25/2013] [Indexed: 12/31/2022]
|
5
|
Villalba-Magdaleno JD, Pérez-Ishiwara G, Serrano-Luna J, Tsutsumi V, Shibayama M. In vivo programmed cell death of Entamoeba histolytica trophozoites in a hamster model of amoebic liver abscess. MICROBIOLOGY-SGM 2011; 157:1489-1499. [PMID: 21349978 DOI: 10.1099/mic.0.047183-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Entamoeba histolytica trophozoites can induce host cell apoptosis, which correlates with the virulence of the parasite. This phenomenon has been seen during the resolution of an inflammatory response and the survival of the parasites. Other studies have shown that E. histolytica trophozoites undergo programmed cell death (PCD) in vitro, but how this process occurs within the mammalian host cell remains unclear. Here, we studied the PCD of E. histolytica trophozoites as part of an in vivo event related to the inflammatory reaction and the host-parasite interaction. Morphological study of amoebic liver abscesses showed only a few E. histolytica trophozoites with peroxidase-positive nuclei identified by terminal deoxynucleotidyltransferase enzyme-mediated dUTP nick end labelling (TUNEL). To better understand PCD following the interaction between amoebae and inflammatory cells, we designed a novel in vivo model using a dialysis bag containing E. histolytica trophozoites, which was surgically placed inside the peritoneal cavity of a hamster and left to interact with the host's exudate components. Amoebae collected from bags were then examined by TUNEL assay, fluorescence-activated cell sorting (FACS) and transmission electron microscopy. Nuclear condensation and DNA fragmentation of E. histolytica trophozoites were observed after exposure to peritoneal exudates, which were mainly composed of neutrophils and macrophages. Our results suggest that production of nitric oxide by inflammatory cells could be involved in PCD of trophozoites. In this modified in vivo system, PCD appears to play a prominent role in the host-parasite interaction and parasite cell death.
Collapse
Affiliation(s)
- José D'Artagnan Villalba-Magdaleno
- Escuela de Ciencias de la Salud, Universidad del Valle de México, Campus Chapultepec, CP 11850, Mexico.,Departamento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN, CP 07300, Mexico
| | | | | | - Víctor Tsutsumi
- Departamento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN, CP 07300, Mexico
| | - Mineko Shibayama
- Departamento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN, CP 07300, Mexico
| |
Collapse
|